How did sulfanilamide lead to the development of sulfa drugs?

The development of sulfa drugs was fundamentally linked to the discovery of the antibacterial properties of Prontosil, a red azo dye. In 1932, German bacteriologist Gerhard Domagk demonstrated that Prontosil could effectively treat Streptococcus infections in mice.213

Subsequent research by French scientists revealed that Prontosil was not the direct antibacterial agent; rather, it was metabolized within the body into sulfanilamide (para-aminobenzenesulfonamide). This identification of sulfanilamide as the active component shifted the focus of medical research toward this compound.231

As the parent compound of the class, sulfanilamide served as the foundation for the development of numerous other sulfa drugs throughout the 1940s. Chemists sought to improve upon the original agent by creating derivatives with greater potency, a wider antibacterial range, or reduced toxicity, leading to the introduction of drugs such as sulfathiazole, sulfadiazine, and sulfamethazine. These synthetic antibiotics marked the beginning of the systematic chemical treatment of bacterial infections in humans.241